Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development.
about
To B or not to B cells-mediate a healthy start to lifeChallenges and treatment options for rheumatoid arthritis during pregnancy.Immune thrombocytopenia in pregnancyExposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases.Hematologic complications of pregnancy.A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy.Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabParvovirus B19 infection presenting with severe erythroid aplastic crisis during pregnancy in a woman with autoimmune hemolytic anemia and alpha-thalassemia trait: a case report.Managing pregnant women with cancer: personal considerations and a review of the literature.Chronic lymphocytic leukaemia during pregnancy: management and thoughtsPregnancy Induced Autoimmune Warm Antibodies Hemolytic Anemia: A Case Report.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Pregnancy complicating Wegener's granulomatosisChemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes.Management of early aggressive rheumatoid arthritis during pregnancy and lactation.Management of RA medications in pregnant patients.Management of hematological malignancies during pregnancy.Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management.Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.Role of IgG antibodies in association with placental function and immunologic diseases in human pregnancy.Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management.High-risk pregnancy and the rheumatologist.Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues.Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy.Neuromyelitis optica and pregnancy.The use of biologics in pregnant patients with rheumatic disease.Current perspective on rituximab in rheumatic diseases.Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation.Placental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis.Antirheumatic biologics in pregnant patients: a call for studies to address the knowledge gap.Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report.
P2860
Q27024986-E4005B51-16F2-484F-8E7A-044C9D984F14Q30249730-D35D9409-72F6-41DC-826D-35F4682C5459Q33387170-6B2CBD28-10ED-424B-8550-D8F7F0E3E16EQ33405115-36813781-92AC-4ED0-AE2E-BD44C3D0E593Q33409852-106CA5D3-10A0-4760-A392-06EB9C8DDB1FQ33844319-286E12B8-E923-4EDC-8185-BFD0BB3B8AA0Q35065425-9B07036B-718D-4668-832D-2030062C05F9Q35186288-0A305A63-949A-43C2-8684-23D8A515BA45Q35572759-F144538E-8872-4A61-9F64-070CEF2131D0Q36319427-A48591DC-5F48-4A97-8AC6-61A44176B17BQ36368981-D08CC586-95FA-4426-8163-639682DA6017Q37031689-1C1CD747-B751-44C0-B548-081D7374A13CQ37186283-EF3125D7-BE90-4909-9740-2B2C45792DD0Q37300632-AAE64FD4-527B-435F-836F-EA9DEE8F93F5Q37510901-061DA055-FED7-4D2D-B7CD-F07A55750444Q37511730-94676381-1CAA-4F36-ABDB-B6A582A7FF0FQ37618667-193C8688-8757-43ED-A6D6-AA0C8FB65B54Q37798387-69661B7E-8DA0-419B-A518-6C22A38E31F0Q37943826-6E135CBB-780C-47C0-9F27-BE9FB0BDEFE5Q38074086-40153E3F-3EB8-40DE-813D-3A07FDE1A777Q38085053-ED9E74C3-3E2E-4DAB-8C96-F7610D4B844BQ38254406-E1D5BCAD-6321-43B6-8B4A-8C131D290E8CQ38283472-E271D40E-6B96-47F6-9D86-407CC3C1763FQ38464355-8CF9B29F-30A3-4487-9F29-7558752E1A44Q38661263-DA5F3D4B-9AC2-4BE3-834F-5B942543F486Q38866313-0C55D4AB-ACAE-47A2-AD0C-4AA6CD652784Q39192359-8013E652-E269-4233-8512-FBBA6B8885BEQ42373160-2CCD1C69-D79F-47E1-B030-E9A8AF8382E7Q43534415-DB9F3D6C-5541-4A28-8D84-6EAA0EE44BF8Q43583667-55447D70-5C03-40BB-94B9-6C47D2AF9340Q49346115-9C7B582E-30F7-47F6-BAE6-64C907529870Q55513989-D2532267-530C-4EA7-9A44-1A88587A1CBA
P2860
Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Rituximab administration in th ...... s neonatal B-cell development.
@ast
Rituximab administration in th ...... s neonatal B-cell development.
@en
type
label
Rituximab administration in th ...... s neonatal B-cell development.
@ast
Rituximab administration in th ...... s neonatal B-cell development.
@en
prefLabel
Rituximab administration in th ...... s neonatal B-cell development.
@ast
Rituximab administration in th ...... s neonatal B-cell development.
@en
P2093
P2860
P356
P1476
Rituximab administration in th ...... s neonatal B-cell development.
@en
P2093
G T J van Well
M W J Schreurs
R M van Elburg
P2860
P304
P356
10.1155/2008/271363
P577
2008-01-01T00:00:00Z